# Electromed, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Electromed, Inc.). ## Overview Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy systems used to help patients with compromised pulmonary function clear mucus and breathe more easily. Its core product is the SmartVest® Airway Clearance System, sold mainly through a direct-to-patient and provider model that works with clinicians, manages insurance reimbursement, and delivers devices for home use, with additional sales into hospitals and selected international markets. ## Products & services • SmartVest® Airway Clearance System • SmartVest Clearway® next-generation HFCWO system • SmartVest SQL® legacy airway clearance system • Related garments, accessories, and replacement parts • Home delivery, setup, training, and patient support • Hospital and acute-care HFCWO device sales - **Airway clearance systems** (88%) — HFCWO devices that help mobilize secretions and improve bronchial drainage. - **Homecare services and support** (7%) — Patient onboarding, training, insurance claims support, and direct fulfillment for home use. - **Hospital and acute-care sales** (5%) — Device sales for inpatient, post-surgical, ICU, and respiratory therapy settings. - SmartVest® Airway Clearance System for home and hospital use - SmartVest Clearway® next-generation HFCWO device - SmartVest SQL® legacy system and ongoing warranty support - Garments, accessories, and replacement components - Direct-to-patient delivery, training, and insurance support - Hospital and acute-care sales for inpatient respiratory therapy ## Customers Electromed sells primarily to patients with physician prescriptions, but the buying process is driven by pulmonologists, cystic fibrosis centers, neuromuscular clinics, and other clinicians who identify candidates for HFCWO therapy. Its end markets include bronchiectasis, cystic fibrosis, neuromuscular disorders, and post-surgical or ventilator-dependent patients, with reimbursement from Medicare, Medicaid, HMOs, and private insurers often determining adoption. The company also serves hospitals, rental companies, and a limited number of HME distributors, especially in the U.S. homecare market. - **Homecare patients with pulmonary disease** (primary) — Patients with bronchiectasis, cystic fibrosis, COPD-related bronchiectasis, and chronic pulmonary conditions who use SmartVest at home because it is prescribed, reimbursable, and supported by direct delivery and training. - **Neuromuscular disease patients** (primary) — Patients with ALS, cerebral palsy, muscular dystrophies, and similar conditions who need airway clearance to manage retained secretions and reduce respiratory complications. - **Pulmonologists and referring clinicians** (primary) — Specialists and clinic staff who identify eligible patients, prescribe therapy, and influence adoption through clinical confidence and referral patterns. - **Hospitals and acute-care institutions** (secondary) — Hospitals, rental companies, and other institutions purchasing HFCWO systems for inpatient, post-surgical, ICU, or infection-related respiratory support. - **HME and respiratory therapy distributors** (secondary) — Limited distribution partners that extend reach in the U.S. homecare market and support incremental sales volume. - Adult pulmonology clinics referring bronchiectasis patients - Cystic fibrosis centers treating chronic mucus clearance needs - Neuromuscular clinics serving ALS, cerebral palsy, and dystrophy patients - Hospitals buying inpatient HFCWO systems and disposables - HME distributors selling into homecare when used as an alternate channel - Patients and caregivers who need home-based therapy and training ## Geography Electromed is primarily a U.S. business, and management says most revenue comes from domestic homecare sales through its physician-referral model. The company also sells in the U.S. hospital market and has select international country approvals, but international demand is still a smaller and less consistent part of the mix. Geography matters because reimbursement, clinician awareness, and sales-force coverage drive adoption, while international distributor demand appears more variable. - U.S. is the core market and the main source of revenue - Domestic homecare is the largest channel and depends on referrals - U.S. hospital sales add a smaller acute-care revenue stream - Select international countries are served through approvals and distributors - International distributor demand is smaller and more volatile ## Strategy Electromed is focused on expanding its direct sales force, increasing awareness of HFCWO therapy, and growing share in adult pulmonology and bronchiectasis. It is also trying to improve the patient experience through product innovation, while preserving its direct-to-patient model that captures both manufacturer and distributor economics. Management is adding territories, strengthening provider education, and selectively using HME distributors as an alternate channel. - **Expand the direct sales force** (short-term) — More territories and reps should increase referrals, approvals, and homecare conversions. - **Increase share in adult pulmonology and bronchiectasis** (medium-term) — This is described as the largest and fastest-growing addressable segment. - **Improve product innovation and patient experience** (medium-term) — Better usability and comfort can support conversion, retention, and clinician preference. - Expand direct sales coverage in high-potential geographies - Grow adult pulmonology and bronchiectasis market share - Increase awareness and clinical adoption of HFCWO therapy - Improve product design and patient experience with Clearway - Use limited HME distributors as a supplemental channel ## Risks Electromed depends on physician referrals, insurance reimbursement, and continued clinical acceptance of HFCWO therapy, so any slowdown in approvals or coverage can directly affect demand. Its business also has long-cycle hospital sales, some exposure to distributor demand, and a concentrated focus on a narrow set of respiratory indications, which makes growth sensitive to market penetration and sales-force execution. As with many medtech companies, it also faces regulatory, reimbursement, and product-development risks, plus accounting judgment around revenue recognition and share-based compensation. - **Insurance reimbursement and coverage risk** [high] — The SmartVest System often relies on Medicare, Medicaid, HMOs, and private payer approval for adoption. - **Physician referral and clinical adoption risk** [high] — The direct-to-patient model depends on pulmonologists and clinicians prescribing therapy and supporting referrals. - **Hospital capital spending cyclicality** [medium] — Hospital revenue can fluctuate with capital budget allocations and long sales cycles. - **Channel mix and distributor execution risk** [medium] — Limited HME and international distributor sales can be uneven and depend on partner performance. - **Regulatory and product clearance risk** [high] — The company depends on FDA clearance and ongoing compliance for marketed devices. - Reimbursement changes could reduce patient access and approval rates - Referral-driven sales depend on clinician awareness and adoption - Hospital orders can be lumpy because capital budgets vary by quarter - International distributor demand is smaller and more volatile - Narrow indication focus increases dependence on bronchiectasis growth - Sales-force expansion may not convert into proportional revenue growth ## Accounting Electromed’s most important accounting issue is revenue recognition, because sales flow through direct patient approvals, insurance reimbursement, and different channels such as homecare, hospital, distributor, and other revenue. Quarterly results can also be affected by lumpy hospital capital orders and changes in approval timing, which makes period-to-period comparisons less linear than annual trends. Share-based compensation is another judgment area because option and performance-award valuation depends on assumptions such as volatility, interest rates, and expected life. - **Revenue recognition** — Affects reported revenue by channel and quarterly comparability - **Quarterly seasonality and lumpy hospital demand** — Can distort near-term growth rates and margin trends - **Share-based compensation valuation** — Affects SG&A and diluted earnings - Revenue recognition depends on when control transfers to the customer - Variable consideration and payer-related adjustments can affect net revenue - Hospital capital orders can create quarter-to-quarter revenue volatility - Share-based compensation uses valuation models and management assumptions - Warranty and support obligations may affect expense timing --- *Last updated: 2026-04-28T20:04:30.550181+00:00*